<?xml version="1.0" encoding="UTF-8"?> <!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd"> <ArticleSet> <Article> <Journal> <PublisherName>njbms</PublisherName> <JournalTitle>NJBMS</JournalTitle> <PISSN>0976-6626</PISSN> <EISSN>2455-1740</EISSN> <Volume-Issue>Volume 2, Issue 1</Volume-Issue> <PartNumber/> <IssueTopic>Multidisciplinary</IssueTopic> <IssueLanguage>English</IssueLanguage> <Season>July - September 2011</Season> <SpecialIssue>N</SpecialIssue> <SupplementaryIssue>N</SupplementaryIssue> <IssueOA>Y</IssueOA> <PubDate> <Year>-0001</Year> <Month>11</Month> <Day>30</Day> </PubDate> <ArticleType>Pharmacology</ArticleType> <ArticleTitle>STUDY TO COMPARE THE CLINICAL EFFICACY OF ORAL THEOPHYLLINE, TIOTROPIUM BROMIDE AND COMBINATION OF FORMOTEROL AND BUDESONIDE IN COPD</ArticleTitle> <SubTitle/> <ArticleLanguage>English</ArticleLanguage> <ArticleOA>Y</ArticleOA> <FirstPage>38</FirstPage> <LastPage>42</LastPage> <AuthorList> <Author> <FirstName>KAVITHA RAJARATHNA</FirstName> <LastName/> <AuthorLanguage>English</AuthorLanguage> <Affiliation/> <CorrespondingAuthor>N</CorrespondingAuthor> <ORCID/> <FirstName>SUSHMA M</FirstName> <LastName/> <AuthorLanguage>English</AuthorLanguage> <Affiliation/> <CorrespondingAuthor>Y</CorrespondingAuthor> <ORCID/> <FirstName>VIJAYA RAJENDRAN</FirstName> <LastName/> <AuthorLanguage>English</AuthorLanguage> <Affiliation/> <CorrespondingAuthor>Y</CorrespondingAuthor> <ORCID/> <FirstName>MURALI MOHAN</FirstName> <LastName>BV</LastName> <AuthorLanguage>English</AuthorLanguage> <Affiliation/> <CorrespondingAuthor>Y</CorrespondingAuthor> <ORCID/> </Author> </AuthorList> <DOI/> <Abstract>COPD is a progressive disease that is fully not reversible. Drugs are used to prevent exacerbations, to improve the quality of life and slow the progression of the disease. In this randomized double-blinded/ double-dummy, parallel group comparative study involving 60 subjects (of whom 46 completed the trial), a comparison of efficacy (FVC) was made between the most commonly used drugs, theophylline, inhaled tiotropium (DPI), and a combination of formoterol-budesonide by inhaler (DPI). Tiotropium bromide improved FVC significantly. Theophylline also improved the lung function, but was associated with the highest drop-out rate probably due to adverse effects. The formoterol-budesonide combination did not provide statistically significant improvements in FVC. Though the individual drugs did help, it was the combination of all the three drugs that best improved the FVC.</Abstract> <AbstractLanguage>English</AbstractLanguage> <Keywords>COPD, theophylline, inhaled tiotropium (DPI), formoterol-budesonide</Keywords> <URLs> <Abstract>https://njbms.in/ubijournal-v1copy/journals/abstract.php?article_id=3281&title=STUDY TO COMPARE THE CLINICAL EFFICACY OF ORAL THEOPHYLLINE, TIOTROPIUM BROMIDE AND COMBINATION OF FORMOTEROL AND BUDESONIDE IN COPD</Abstract> </URLs> <References> <ReferencesarticleTitle>References</ReferencesarticleTitle> <ReferencesfirstPage>16</ReferencesfirstPage> <ReferenceslastPage>19</ReferenceslastPage> <References/> </References> </Journal> </Article> </ArticleSet>